Literature DB >> 17225253

Method for generation of human hyperdiversified antibody fragment library.

Philippe Mondon1, Nathalie Souyris, Laurent Douchy, Fabien Crozet, Khalil Bouayadi, Hakim Kharrat.   

Abstract

The selection of antibody fragments from libraries using in vitro screening technologies has proven to be a very good alternative to the classical hybridoma technology, and has overcome the laborious process of antibody humanization. However, the complexity of the library is critical in the probability of being able to directly isolate a high affinity antibody specific to a target. We report a method to make hyperdiversified antibody fragment libraries, based on human immunoglobulin variable genes mimicking the somatic hypermutation process. This mutagenesis technology, MutaGen, was used for the first time on the entire variable domain (frameworks and CDRs) of large repertoires of human variable antibody domains. Our MutaGen process uses low-fidelity human polymerases, known as mutases, suggested to be involved in the somatic hypermutation process of immunoglobulin genes. Depending on the mutases used, we generated complementary mutation patterns with randomly distributed mutations. The libraries were generated with an average of 1.8 mutations per 100 amino acids. The hyperdiversified antibody fragment libraries constructed with our process should enable the selection of antibody fragments specific to virtually any target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225253     DOI: 10.1002/biot.200600205

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  9 in total

1.  Combinatorial engineering to enhance thermostability of amylosucrase.

Authors:  Stéphane Emond; Isabelle André; Kais Jaziri; Gabrielle Potocki-Véronèse; Philippe Mondon; Khalil Bouayadi; Hakim Kharrat; Pierre Monsan; Magali Remaud-Simeon
Journal:  Protein Sci       Date:  2008-04-25       Impact factor: 6.725

2.  Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Authors:  Yassamine Lazrek; Olivier Dubreuil; Véronique Garambois; Nadège Gaborit; Christel Larbouret; Christophe Le Clorennec; Gaelle Thomas; Wilhem Leconet; Marta Jarlier; Martine Pugnière; Nadia Vié; Bruno Robert; Céline Monnet; Khalil Bouayadi; Hakim Kharrat; Philippe Mondon; André Pèlegrin; Thierry Chardès
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

3.  Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.

Authors:  Céline Monnet; Sylvie Jorieux; Nathalie Souyris; Ouafa Zaki; Alexandra Jacquet; Nathalie Fournier; Fabien Crozet; Christophe de Romeuf; Khalil Bouayadi; Rémi Urbain; Christian K Behrens; Philippe Mondon; Alexandre Fontayne
Journal:  MAbs       Date:  2014-01-15       Impact factor: 5.857

4.  Modern Technologies for Creating Synthetic Antibodies for Clinical application.

Authors:  S M Deyev; E N Lebedenko
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

Review 5.  Antibody Fragments as Probe in Biosensor Development.

Authors:  Dirk Saerens; Lieven Huang; Kristien Bonroy; Serge Muyldermans
Journal:  Sensors (Basel)       Date:  2008-08-08       Impact factor: 3.576

6.  Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.

Authors:  Céline Monnet; Sylvie Jorieux; Rémi Urbain; Nathalie Fournier; Khalil Bouayadi; Christophe De Romeuf; Christian K Behrens; Alexandre Fontayne; Philippe Mondon
Journal:  Front Immunol       Date:  2015-02-04       Impact factor: 7.561

7.  The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.

Authors:  Pauline Estupina; Alexandre Fontayne; Jean-Marc Barret; Nathalie Kersual; Olivier Dubreuil; Marion Le Blay; Alexandre Pichard; Marta Jarlier; Martine Pugnière; Maëva Chauvin; Thierry Chardès; Jean-Pierre Pouget; Emmanuel Deshayes; Alexis Rossignol; Toufik Abache; Christophe de Romeuf; Aurélie Terrier; Lucie Verhaeghe; Christine Gaucher; Jean-François Prost; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Oncotarget       Date:  2017-06-06

8.  An innovative flow cytometry method to screen human scFv-phages selected by in vivo phage-display in an animal model of atherosclerosis.

Authors:  Audrey Hemadou; Jeanny Laroche-Traineau; Ségolène Antoine; Philippe Mondon; Alexandre Fontayne; Yannick Le Priol; Stéphane Claverol; Stéphane Sanchez; Martine Cerutti; Florence Ottones; Gisèle Clofent-Sanchez; Marie-Josée Jacobin-Valat
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

9.  In Vivo Human Single-Chain Fragment Variable Phage Display-Assisted Identification of Galectin-3 as a New Biomarker of Atherosclerosis.

Authors:  Audrey Hemadou; Alexandre Fontayne; Jeanny Laroche-Traineau; Florence Ottones; Philippe Mondon; Stéphane Claverol; Éric Ducasse; Stéphane Sanchez; Sarah Mohamad; Cyril Lorenzato; Martine Duonor-Cerutti; Gisèle Clofent-Sanchez; Marie-Josée Jacobin-Valat
Journal:  J Am Heart Assoc       Date:  2021-09-25       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.